Occult metastases are prognostic variables in patients with breast cancer who have negative sentinel lymph node biopsies, but the difference in five-year outcome is very small, according to a study published online Jan. 19 in the New England Journal of Medicine.
WEDNESDAY, Jan. 19 (HealthDay News) -- Occult metastases are prognostic variables in patients with breast cancer who have negative sentinel lymph node biopsies, but the difference in five-year outcome is very small, according to a study published online Jan. 19 in the New England Journal of Medicine.
Donald L. Weaver, M.D., from the University of Vermont College of Medicine in Burlington, and colleagues randomized 3,887 women with breast cancer to sentinel-lymph-node biopsy plus axillary dissection or biopsy alone. Biopsies of pathologically negative sentinel lymph nodes were further analyzed to detect all macrometastases larger than 2 mm.
The researchers identified occult metastases in 15.9 percent of the patients. Analysis indicated a significant difference between patients in whom occult metastases were detected and those in whom they were not detected with respect to overall survival, disease-free survival, and distant disease-free interval. The adjusted hazard ratios were 1.4 for death, 1.3 for any outcome event, and 1.3 for distant disease. Kaplan-Meier five-year overall survival estimates were 94.6 percent in those with occult metastases and 95.8 percent in patients without occult metastases.
"These data do not indicate a clinical benefit of additional evaluation, including immunohistochemical analysis, of initially negative sentinel nodes in patients with breast cancer," the authors write.
AbstractFull Text (subscription or payment may be required)
Related ContentPrimary breast tumor characteristics are found in distant metastasesIdentification of the Functional Role of Peroxiredoxin 6 in the Progression of Breast Cancer
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More